评估放疗对乳腺癌患者血液样本中 CCL5/miR-214 -3p/MALAT1 基因表达的影响

IF 1.5 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Fazlollah Shokri, Hossein Mozdarani, Mir Davood Omrani
{"title":"评估放疗对乳腺癌患者血液样本中 CCL5/miR-214 -3p/MALAT1 基因表达的影响","authors":"Fazlollah Shokri, Hossein Mozdarani, Mir Davood Omrani","doi":"10.22088/IJMCM.BUMS.11.3.244","DOIUrl":null,"url":null,"abstract":"<p><p>Current cancer therapies include chemotherapy, radiation therapy, immunotherapy, and surgery. Despite these treatment methods, a major point in cancer treatment is early detection. RNAs (mRNA, miRNAs, and LncRNA) can be used as markers to improve cancer diagnosis and treatment. This research examined how radiotherapy affected <i>CCL5, miR-214, and MALAT-1</i> gene expression in the immune pathway in peripheral blood samples from radiation therapy-treated breast cancer patients. Before and after radiotherapy, peripheral blood was collected from 15 patients in four steps. Blood samples were collected in an outpatient facility from 20 healthy female volunteers with no history of malignant or inflammatory conditions. RNA was extracted from the blood samples and cDNA was synthesized. <i>CCL5, miR-214</i>, and <i>MALAT-1</i> gene expression were determined by real-time polymerase chain reaction (RT-PCR). <i>CCL5</i> protein levels in the serum were determined in 80 samples (60 BC and 20 healthy controls) using Quantikine Enzyme-Linked Immunosorbent Assay (ELISA) kits (R&D Systems). The data were then statistically evaluated. There was a significant difference between <i>CCL5</i> levels in tumoral and adjacent normal blood samples (p < 0.05). The results also show that the level of gene expression and serum concentration of <i>CCL5</i> protein in different phases of radiotherapy is significantly different. On the other hand, the expression level of the <i>miR-214</i> gene was significantly decreased in patients compared to the control group, but this decrease was not significant for the <i>MALAT-1</i> gene (p< 0.05). Also, after each stage of radiotherapy, the expression level of these two genes showed a decrease, but in the fourth week after radiotherapy, this decrease was significant (p< 0.05). Radiotherapy is associated with a decrease in the expression of <i>miR-214</i> and <i>MALAT-1</i>, as a result, an increase in the expression of <i>CCL5</i>. An increase in the concentration of <i>CCL5</i> protein is accompanied by an increase in the level of monocytes, which ultimately causes the infiltration of macrophages and can ultimately cause cancer recurrence. It is suggested that these genes can probably be used as diagnostic and therapeutic radiotherapy markers in breast cancer.</p>","PeriodicalId":14152,"journal":{"name":"International Journal of Molecular and Cellular Medicine","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c4/58/ijmcm-11-244.PMC10440003.pdf","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the Effect of Radiotherapy on CCL5/miR-214 -3p/MALAT1 Genes Expression in Blood Samples of Breast Cancer Patients.\",\"authors\":\"Fazlollah Shokri, Hossein Mozdarani, Mir Davood Omrani\",\"doi\":\"10.22088/IJMCM.BUMS.11.3.244\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Current cancer therapies include chemotherapy, radiation therapy, immunotherapy, and surgery. Despite these treatment methods, a major point in cancer treatment is early detection. RNAs (mRNA, miRNAs, and LncRNA) can be used as markers to improve cancer diagnosis and treatment. This research examined how radiotherapy affected <i>CCL5, miR-214, and MALAT-1</i> gene expression in the immune pathway in peripheral blood samples from radiation therapy-treated breast cancer patients. Before and after radiotherapy, peripheral blood was collected from 15 patients in four steps. Blood samples were collected in an outpatient facility from 20 healthy female volunteers with no history of malignant or inflammatory conditions. RNA was extracted from the blood samples and cDNA was synthesized. <i>CCL5, miR-214</i>, and <i>MALAT-1</i> gene expression were determined by real-time polymerase chain reaction (RT-PCR). <i>CCL5</i> protein levels in the serum were determined in 80 samples (60 BC and 20 healthy controls) using Quantikine Enzyme-Linked Immunosorbent Assay (ELISA) kits (R&D Systems). The data were then statistically evaluated. There was a significant difference between <i>CCL5</i> levels in tumoral and adjacent normal blood samples (p < 0.05). The results also show that the level of gene expression and serum concentration of <i>CCL5</i> protein in different phases of radiotherapy is significantly different. On the other hand, the expression level of the <i>miR-214</i> gene was significantly decreased in patients compared to the control group, but this decrease was not significant for the <i>MALAT-1</i> gene (p< 0.05). Also, after each stage of radiotherapy, the expression level of these two genes showed a decrease, but in the fourth week after radiotherapy, this decrease was significant (p< 0.05). Radiotherapy is associated with a decrease in the expression of <i>miR-214</i> and <i>MALAT-1</i>, as a result, an increase in the expression of <i>CCL5</i>. An increase in the concentration of <i>CCL5</i> protein is accompanied by an increase in the level of monocytes, which ultimately causes the infiltration of macrophages and can ultimately cause cancer recurrence. It is suggested that these genes can probably be used as diagnostic and therapeutic radiotherapy markers in breast cancer.</p>\",\"PeriodicalId\":14152,\"journal\":{\"name\":\"International Journal of Molecular and Cellular Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c4/58/ijmcm-11-244.PMC10440003.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Molecular and Cellular Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22088/IJMCM.BUMS.11.3.244\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Molecular and Cellular Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22088/IJMCM.BUMS.11.3.244","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

目前的癌症疗法包括化疗、放疗、免疫疗法和手术。尽管有这些治疗方法,但癌症治疗的一个重点是早期检测。RNA(mRNA、miRNA 和 LncRNA)可作为标记物来改善癌症诊断和治疗。这项研究考察了放疗如何影响接受放疗的乳腺癌患者外周血样本中免疫通路中的CCL5、miR-214和MALAT-1基因表达。在放疗前后,分四个步骤采集了 15 名患者的外周血。在门诊设施中采集了 20 名无恶性或炎症病史的健康女性志愿者的血液样本。从血样中提取 RNA 并合成 cDNA。通过实时聚合酶链反应(RT-PCR)测定 CCL5、miR-214 和 MALAT-1 基因的表达。使用定量酶联免疫吸附试验(ELISA)试剂盒(R&D Systems)测定了 80 份样本(60 份 BC 样本和 20 份健康对照样本)血清中的 CCL5 蛋白水平。然后对数据进行统计评估。肿瘤和邻近正常血液样本中的 CCL5 水平存在明显差异(P < 0.05)。结果还显示,在放疗的不同阶段,CCL5 蛋白的基因表达水平和血清浓度有显著差异。另一方面,与对照组相比,患者体内 miR-214 基因的表达水平明显下降,但 MALAT-1 基因的表达水平下降不明显(p< 0.05)。此外,在每个阶段的放疗后,这两个基因的表达水平都出现了下降,但在放疗后第四周,这种下降是显著的(p< 0.05)。放疗与 miR-214 和 MALAT-1 的表达减少有关,因此会导致 CCL5 的表达增加。CCL5 蛋白浓度的增加伴随着单核细胞水平的增加,最终导致巨噬细胞的浸润,并最终导致癌症复发。这表明,这些基因很可能可用作乳腺癌的诊断和治疗放疗标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Evaluation of the Effect of Radiotherapy on CCL5/miR-214 -3p/MALAT1 Genes Expression in Blood Samples of Breast Cancer Patients.

Evaluation of the Effect of Radiotherapy on CCL5/miR-214 -3p/MALAT1 Genes Expression in Blood Samples of Breast Cancer Patients.

Evaluation of the Effect of Radiotherapy on CCL5/miR-214 -3p/MALAT1 Genes Expression in Blood Samples of Breast Cancer Patients.

Evaluation of the Effect of Radiotherapy on CCL5/miR-214 -3p/MALAT1 Genes Expression in Blood Samples of Breast Cancer Patients.

Current cancer therapies include chemotherapy, radiation therapy, immunotherapy, and surgery. Despite these treatment methods, a major point in cancer treatment is early detection. RNAs (mRNA, miRNAs, and LncRNA) can be used as markers to improve cancer diagnosis and treatment. This research examined how radiotherapy affected CCL5, miR-214, and MALAT-1 gene expression in the immune pathway in peripheral blood samples from radiation therapy-treated breast cancer patients. Before and after radiotherapy, peripheral blood was collected from 15 patients in four steps. Blood samples were collected in an outpatient facility from 20 healthy female volunteers with no history of malignant or inflammatory conditions. RNA was extracted from the blood samples and cDNA was synthesized. CCL5, miR-214, and MALAT-1 gene expression were determined by real-time polymerase chain reaction (RT-PCR). CCL5 protein levels in the serum were determined in 80 samples (60 BC and 20 healthy controls) using Quantikine Enzyme-Linked Immunosorbent Assay (ELISA) kits (R&D Systems). The data were then statistically evaluated. There was a significant difference between CCL5 levels in tumoral and adjacent normal blood samples (p < 0.05). The results also show that the level of gene expression and serum concentration of CCL5 protein in different phases of radiotherapy is significantly different. On the other hand, the expression level of the miR-214 gene was significantly decreased in patients compared to the control group, but this decrease was not significant for the MALAT-1 gene (p< 0.05). Also, after each stage of radiotherapy, the expression level of these two genes showed a decrease, but in the fourth week after radiotherapy, this decrease was significant (p< 0.05). Radiotherapy is associated with a decrease in the expression of miR-214 and MALAT-1, as a result, an increase in the expression of CCL5. An increase in the concentration of CCL5 protein is accompanied by an increase in the level of monocytes, which ultimately causes the infiltration of macrophages and can ultimately cause cancer recurrence. It is suggested that these genes can probably be used as diagnostic and therapeutic radiotherapy markers in breast cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.60
自引率
0.00%
发文量
0
期刊介绍: The International Journal of Molecular and Cellular Medicine (IJMCM) is a peer-reviewed, quarterly publication of Cellular and Molecular Biology Research Center (CMBRC), Babol University of Medical Sciences, Babol, Iran. The journal covers all cellular & molecular biology and medicine disciplines such as the genetic basis of disease, biomarker discovery in diagnosis and treatment, genomics and proteomics, bioinformatics, computer applications in human biology, stem cells and tissue engineering, medical biotechnology, nanomedicine, cellular processes related to growth, death and survival, clinical biochemistry, molecular & cellular immunology, molecular and cellular aspects of infectious disease and cancer research. IJMCM is a free access journal. All open access articles published in IJMCM are distributed under the terms of the Creative Commons Attribution CC BY. The journal doesn''t have any submission and article processing charges (APCs).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信